Detailed medication introduction of Erdafitinib/Bocco

Erdafitinib is a targeted therapy drug mainly used to treat advanced urothelial cancer (bladder cancer) carrying FGFR (fibroblast growth factor receptor) gene mutations, especially those whose disease has progressed after chemotherapy. It is a small molecule tyrosine kinase inhibitor that specifically targets receptors such as FGFR1, FGFR2, FGFR3 and FGFR4, thereby blocking the growth and expansion of cancer cells. The FGFR pathway plays an important role in the occurrence and development of various tumors. Therefore, by inhibiting this pathway, erdafitinib can effectively slow down tumor growth, especially in urothelial cancer, which has a significant clinical effect.

The dose of erlotinib usually starts at 8 mg once daily and can be adjusted according to the patient's tolerance, up to 9 mg, 10 mg, 12 mg or higher. Patients need to take the medicine at a fixed time every day, whether eating or not, taking the tablet directly and swallowing it with water. The dose may be further adjusted based on the patient's liver and kidney function and response to the drug. Especially in patients with hepatic insufficiency or other complications, the metabolism of the drug needs to be closely monitored to ensure that the patient can use it safely.

In addition, the duration of treatment with erdafitinib depends on the individual patient response. Patients often need periodic imaging and laboratory tests to evaluate the effectiveness of treatment and monitor possible side effects. During the course of drug treatment, the doctor may make corresponding adjustments to the treatment plan based on the examination results, including increasing or decreasing the drug dose or suspending treatment.

For patients with advanced urothelial cancer who carryFGFR gene mutations, Boco, as an innovative targeted drug, provides a new treatment option for those patients who have failed traditional chemotherapy. The approval of erdafitinib marks the further development of precision medicine in cancer treatment, which helps patients improve survival rates and quality of life by specifically targeting the molecular mechanisms of cancer.

Reference materials：https://www.balversa.com/